Zobrazeno 1 - 7
of 7
pro vyhledávání: '"James F. Jiang"'
Autor:
Mehmet A. Bilen, James F. Jiang, Caroline S. Jansen, Jacqueline T. Brown, Lara R. Harik, Aarti Sekhar, Haydn Kissick, Shishir K. Maithel, Omer Kucuk, Bradley Carthon, Viraj A. Master
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
IntroductionCabozantinib (XL-184) is a small molecule inhibitor of the tyrosine kinases c-Met, AXL, and VEGFR2 that has been shown to reduce tumor growth, metastasis, and angiogenesis. After the promising results from the METEOR and CABOSUN trials, c
Externí odkaz:
https://doaj.org/article/9bd82e94fe14462488e08962f8af3568
Publikováno v:
Asian Journal of Andrology, Vol 26, Iss 3, Pp 333-334 (2024)
Externí odkaz:
https://doaj.org/article/3f069b2879a845e7a871fa08b26b8845
Publikováno v:
Journal of health care for the poor and underserved. 33(3)
To compare percutaneous tibial nerve stimulation (PTNS) compliance rate at a safety-net versus tertiary academic hospital and assess the impact of social determinants on compliance.Retrospective cohort study of 133 patients at Grady Memorial Hospital
Autor:
James F. Jiang, Jessica Hammett, Elizabeth J. Traore, Dattatraya Patil, Christopher P. Filson
Publikováno v:
Urology. 142:87-93
OBJECTIVE To evaluate utilization of third-line overactive bladder (OAB) treatments including percutaneous tibial nerve stimulation (PTNS), sacral nerve stimulation (SNS), and intradetrusor botulinum toxin A (BTX) among privately insured patients and
Autor:
Aaron H. Lay, Christopher P. Filson, Brian Pettitt-Schieber, Andrew K. Leung, Viraj Master, Jessica Hammett, Margracious Brown, Renee L. Thomas, K. Jeff Carney, Dennis Hafford, James F. Jiang, Reza Nabavizadeh
Publikováno v:
Journal of Urology. 203:385-391
We investigated efficacy and compliance related to percutaneous tibial nerve stimulation in patients treated for overactive bladder at a large, urban safety net hospital.Consecutive patients who underwent percutaneous tibial nerve stimulation at Grad
Publikováno v:
World Neurosurgery. 124:e417-e423
Patients with refractory chronic primary headache disorders have extremely debilitating symptoms, severe comorbidities (e.g., anxiety, depression), and a significant reduction in quality of life. The headaches are extremely difficult to treat, as the
Autor:
James F. Jiang, Andrew K. Leung, Brian Pettitt-Schieber, Reza Nabavizadeh, Renee L. Thomas, Margracious Brown, Dennis Hafford, Aaron H. Lay, Jessica Hammett, K. Jeff Carney, Christopher P. Filson, Viraj A. Master
Publikováno v:
Journal of Urology. 203:391-391